Cantor Fitzgerald Estimates MannKind FY2025 Earnings

MannKind Co. (NASDAQ:MNKD) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of MannKind in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will post earnings per share of $0.34 for the year. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.04. The company had revenue of $70.08 million during the quarter, compared to analyst estimates of $77.27 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%.

Other analysts have also issued research reports about the company. StockNews.com lowered MannKind from a “buy” rating to a “hold” rating in a report on Saturday, December 7th. Wells Fargo & Company began coverage on MannKind in a report on Friday, December 20th. They issued an “overweight” rating and a $9.00 price objective for the company. Finally, Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $7.00 to $10.00 in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $9.07.

MannKind Trading Up 2.2 %

MannKind stock opened at $6.17 on Thursday. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 88.14 and a beta of 1.29. The stock has a fifty day simple moving average of $6.51 and a two-hundred day simple moving average of $6.26. MannKind has a 12 month low of $3.17 and a 12 month high of $7.63.

Hedge Funds Weigh In On MannKind

Several large investors have recently made changes to their positions in MNKD. Dimensional Fund Advisors LP purchased a new position in shares of MannKind in the second quarter valued at about $1,524,000. Renaissance Technologies LLC purchased a new stake in shares of MannKind in the second quarter worth about $67,000. AQR Capital Management LLC lifted its position in shares of MannKind by 8.1% in the second quarter. AQR Capital Management LLC now owns 42,730 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 3,214 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of MannKind by 17.5% in the second quarter. Deerfield Management Company L.P. Series C now owns 196,577 shares of the biopharmaceutical company’s stock worth $1,026,000 after buying an additional 29,299 shares in the last quarter. Finally, Dark Forest Capital Management LP lifted its position in shares of MannKind by 1,551.2% in the second quarter. Dark Forest Capital Management LP now owns 275,970 shares of the biopharmaceutical company’s stock worth $1,441,000 after buying an additional 259,257 shares in the last quarter. 49.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at MannKind

In other news, Director Steven B. Binder sold 67,536 shares of the business’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.89, for a total value of $465,323.04. Following the transaction, the director now directly owns 1,075,026 shares in the company, valued at $7,406,929.14. The trade was a 5.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stuart A. Tross sold 55,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total value of $403,700.00. Following the completion of the transaction, the insider now owns 967,191 shares in the company, valued at $7,099,181.94. The trade was a 5.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 190,075 shares of company stock worth $1,325,587. Corporate insiders own 3.00% of the company’s stock.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.